Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Apr 24, 2008 | Senior VP, Drug Development | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | -- | 4,924 | |
| Apr 16, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 578 | $10.00 | 66,449 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 800 | $10.00 | 69,649 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 400 | $10.01 | 69,249 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 522 | $10.02 | 68,727 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $10.15 | 68,627 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 700 | $10.18 | 67,927 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $10.26 | 67,827 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 400 | $10.27 | 67,427 | |
| Apr 15, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 200 | $10.28 | 67,227 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.